Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 787 across all filing types
Latest filing 2025-07-03 Major Shareholding Noti…
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Innehavare', 'Transaktionen', 'Andel') for a specific instrument ('Aktie SE0020353928') by an entity ('Nordnet AB (publ)'). It specifies the date of the transaction (2025-07-02), the resulting ownership percentage (7.3261%), and references regulatory requirements ('LHF 4 kap. 2§', 'FI'). This structure is characteristic of a notification regarding a change in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is a direct filing/report of the transaction, not an announcement of a report.
2025-07-03 Swedish
Ändring av antalet aktier och röster i Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short press release dated June 30, 2025, titled "Ändring av antalet aktier och röster i Moberg Pharma AB (publ)" (Change in the number of shares and votes in Moberg Pharma AB (publ)). It explicitly states that the total number of shares has increased due to an issuance and subsequent conversion/reacquisition related to incentive programs. This directly concerns the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Given the content, SHA is the most precise classification.
2025-06-30 Swedish
New number of shares and votes in Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release announcing a change in the total number of outstanding shares and votes due to the issuance of new shares related to an incentive program. Specifically, it states the total number of common shares increased to 48,712,067 following the issuance of 832,213 shares. This directly relates to changes in the company's capital structure (share count). Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements detailing changes in the number of shares outstanding, even if the context is related to an incentive program.
2025-06-30 English
Changes to Moberg Pharma´s Management
Board/Management Information Classification · 98% confidence The document is a press release announcing specific changes within the company's leadership structure: the departure of the Chief Medical Officer and the Head of Supply, and the resulting streamlined management team. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2025-06-25 English
Förändringar i Moberg Pharmas ledningsgrupp
Board/Management Information Classification · 100% confidence The document is a press release dated June 25, 2025, titled "Förändringar i Moberg Pharmas ledningsgrupp" (Changes in Moberg Pharma's management group). It explicitly states that the CMO (Anders Bröijersén) and Head of Supply (Robert Ehrl) are leaving the management group as a consequence of a resource review following the Q1 2025 interim report. This content directly relates to changes in senior management personnel. This matches the definition for Board/Management Information (MANG). The document length is short (2561 chars), but it is a substantive announcement of management changes, not merely an announcement of another report's publication, thus MANG is preferred over RPA or RNS.
2025-06-25 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Sälj' - Sell transaction) for Moberg Pharma AB, specifically reporting the new holding percentage (4.80656%) and the number of shares held by Avanza Bank Holding AB for its pension customers. This type of filing, which reports when an investor crosses a significant ownership threshold (5% in this case, although the resulting holding is just below it, the filing is triggered by the transaction), is classified as a Major Shareholding Notification. The Swedish context and the structure strongly align with regulatory filings concerning significant ownership changes, matching the definition for Major Shareholding Notification (MRQ). The document is short and regulatory in nature, not a full report or an announcement of a report.
2025-06-18 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.